Day 1: Thursday, February 6, 2025

Opening & keynote lecture 1 - 12:30 - 13:15

Room Schweitzer

Chairs: Anna Sureda (Spain) & Maria Themeli (The Netherlands)

Carl June (United States)

Keynote Lecture

Acute and chronic leukemias - 13:15 - 14:15

Room Schweitzer

Chairs: Ulrich Jäger (Austria) & Mette Hazenberg (The Netherlands)

Lessons learnt from AML

Nela Klein Gonzalez (Spain)

CAR-T cells for CLL: When? for whom?

Tanya Siddiqui (United States)

Adult ALL

Claire Roddie (United Kingdom)

Pediatric ALL

Peter Bader (Germany)

Coffee break - 14:15 - 14:45

Translational I: New frontiers and innovations - 14:45 - 16:15

Room Schweitzer

Chairs: Melita Irving (Switzerland) & Stanley Riddell (United States)

Special lecture

Stanley Riddel (United States)

Genome editing methods

Will Nyberg (Sweden)

Pooled CRISPR Screens: Reprogramming Therapeutic T Cells

Franzisca Blaeschke (Germany)

Base editing to improve CAR T function

Judith Feucht (Germany)

Patient in focus: Delving into CAR T-Cell therapy accessibility challenges - 14:45 - 16:15

Room Cassin

Chairs: Jana Pelouchova (Czechia) & Natacha Bolaños (Spain)

Economic and organizational impact of the introduction of CAR-T-cell therapy

Speaker to be announced

Hospital exemption as a route for patient access to CAR-T therapy, enabling on-site manufacturing with greater flexibility and reduced costs for sustainable access

Manel Juan (Spain)

A patient's story of navigating cross border CAR-T cell therapy

Speaker to be announced

Recommendations for Health System Solutions

Liora Bowers (France)

Satellite symposium by BMS - 16:30 - 17:15

Room Schweitzer

Coffee break - 17:15 - 17:30

Oral Session 1: Preclinical - 17:30 - 18:30

Room Schweitzer

CD19-DIRECTED CAR T CELL THERAPY IN 5 PATIENTS WITH REFRACTORY MULTIPLE SCLEROSIS

Johanna Richter (Germany)

RAPCABTAGENE AUTOLEUCEL (YTB323) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): UPDATED RESULTS FROM A PHASE II CLINICAL TRIAL

Pere Barba (Spain)

REDUCTION IN EXTRAFOLLICULAR B CELL RESPONSES IN SLE PATIENTS AFTER CAR-T CELL THERAPY

Danae-Mona Nöthling (Germany)

THERAPY RELATED MYELOID NEOPLASM FOLLOWING CD19 DIRECTED CAR T CELLS FOR PATIENTS WITH B-CELL LYMPHOMA

Nicolas Gazeau (France)

AUTOCRINE GLUCOCORTICOID SIGNALING IN HORMONALLY ACTIVE CANCERS INDUCES ANTIGEN EXPRESSION FOR CAR-T CELL THERAPY

Marc Philipp Schauer (Germany)

IDENTIFICATION OF TUMOR-DERIVED MICRORNAI25A AS A CATALYST FOR CAR-T CELL DYSFUNCTION IN B CELL MALIGNANCIES

Olivia Sirpilla (United States)

CAFFEINE-REGULATED MOLECULAR SWITCHES FOR FUNCTIONAL CONTROL OF CAR-T CELLS Elise Sylvander (Austria)

DISTINCT PREFERENCES OF CD8+ AND CD4+ CAR-T CELLS FOR TRANSCRIPTION FACTOR ENHANCEMENT Fabian Freitag (Germany)

CTLA-4-BASED ACTIVATION INDUCIBLE COSTIMULATORY RECEPTORS BESTOW CAR-T CELLS WITH SAFE, TUMOR-RESTRICTED, MULTI-TARGETING AND IMPROVED FUNCTIONAL FITNESS
Afroditi Katsarou (The Netherlands)

Keynote lecture 2 - 18:45 - 19:15

Room Schweitzer

Chairs: Anna Sureda (Spain) & Maria Themeli (The Netherlands)

Keynote Lecture

Monica Casucci (Italy)

Welcome reception + Poster session - 19:15 - 20:15

Hall Rhin

Day 2: Friday, February 7, 2025

Clinical management session - 08:30 - 09:30

Room Schweitzer

Chair: Ibrahim Yakoub-Agha (France)

Secondary malignancies after CAR T

Fabio Ciceri (Italy)

Infection complication after CAR T

Lidia Gil (Poland)

Cardiac complication after CAR T

Roni Shouval (United States)

European projects and networks - 08:30 - 09:30

Room Cassin

Chair: Jürgen Kuball (The Netherlands)

GoCART

Christian Chabannon (France)

T-FITNESS

Luca Gattinoni (Germany)

JOIN4ATMP

Annette Künkele (Germany)

AIDPATH

Carmen Sanges (Germany)

Nurses Track - Session 1 - 08:30 - 09:30

Room Curie

Chairs: Michelle Kenyon (United Kingdom) & Mairead Ni Chonghaile (Ireland)

Opening comments

Michelle Kenyon (United Kingdom) & Mairead Ni Chonghaile (Ireland)

Keynote lecture

Anna Sureda (Spain)

Keynote: Equity and access to CART

Nico Gagelmann (Germany)

Panel discussion

All speakers

Solid tumors - 09:30 - 10:30

Room Schweitzer

Chair: Annette Künkele (Germany)

Special speaker: CAR T for Solid Tumors/Glioblastoma study

Michael Hudecek (Germany)

Treatment of solid tumors with NKG2D-based CAR T-cells

John Maher (United Kingdom)

Glioblastoma

Denis Migliorni (Switzerland)

Next-generation CAR-T cells for solid tumors and hematological malignancies

Sonia Guedan (Spain)

Nurses Track - Session 2: Fundamentals of cell and gene therapy - 09:30 - 10:30

Room Curie

Chairs: Michelle Kenyon (United Kingdom) & Mairead Ni Chonghaile (Ireland)

Prehabilitation and rehabilitation - frailty, psychological and nutritional needs

Orla McCourt (United Kingdom)

Acute toxicity management

Ruth Clout (United Kingdom)

Late complications

Edoardo Campodonico (Italy)

O&A

All speakers

Coffee break - 10:30 - 11:00

Tech Talk by Kyverna - 10:45 - 10:55

Gallery Schweitzer

Manufacturing and regulatory aspects - 11:00 - 12:30

Room Schweitzer

Chair: Ulrike Köhl (Germany)

GMP lentiviral manufacturing

Hugo Calderón (Spain)

Regulatory aspect

Attila Sebe (Germany)

Facilitating CAR T cell manufacturing: short-term CAR T cells and in vivo CAR delivery are moving into clinics

Christian Buchholtz (Germany)

Reimbursement of CAR T cells

Julio Delgado (Spain)

Panel discussion

All speakers

Clinical cases session - 11:00 - 12:00

Room Cassin

Chairs: Nico Gagelmann (Germany) & Koray Yalcin (Türkiye)

CAR T for autoimmune diseases

Fabian Müller (Germany)

Allogenetic CAR T

Reuben Benjamin (United Kingdom)

Gene therapy for hemoglobinopathies

Marina Cavazzana (France)

Pre/post poll questions

All spakers

Nurses Track - Session 3: Fundamentals of cell and gene therapy - 11:00 - 12:30

Room Curie

Chairs: Michelle Kenyon (United Kingdom) & Mairead Ni Chonghaile (Ireland)

Update CART in hemato-oncology

Annalisa Ruggeri (Italy)

CART in autoimmune disease indications

Rafaella Greco (Italy)

Bispecifics - where do they fit?

Jeremy Deuel (Switzerland)

Gene therapy in hemoglobinopathy

Hilda Mekelenkamp (The Netherlands)

Lunch - 12:30 - 13:30

Satellite Symposium by Gilead - 13:00 - 13:45

Room Schweitzer

Translational II: CAR T designs, models and mechanisms - 14:00 - 15:30

Room Schweitzer

Chair: Sonia Guedan (Spain) & Maik Luu (Germany)

Mitochondrial transfer for adoptive T cell therapy

Luca Gattinoni (Germany)

Targeting metabolites / metabolic reprogramming

Mattias Wenes (Switzerland)

Engineered T cells in the tumor microenvironment

Melita Irving (Switzerland)

Models for CRS, ICANs, ICAHT

Robert Zeiser (Germany)

Chairs: Michelle Kenyon (United Kingdom) & Mairead Ni Chonghaile (Ireland)

Wearables

Speaker to be announced

Remote monitoring CARAMA

Fanny Colin (France)

PPIE & CART service evaluatio

Britt Snoek (The Netherlands)

The last bridge - How patients experience CAR T-cell therapy and possible fields of action for nurses in the course of the treatment

Verena Leinemann (Austria)

Coffee break - 15:30 - 16:00

Industry theater by BMS - 15:35 - 15:55

Gallery Schweitzer

Keynote lecture 3 - 17:00 - 17:30

Room Schweitzer

Chairs: Anna Sureda (Spain) & Maria Themeli (The Netherlands)

Keynote Lecture

Martin Pule (United Kingdom)

New indications and other cell types - 17:30 - 19:00

Room Schweitzer

Chairs: Raffaela Greco (Italy) & Annalisa Ruggeri (Italy)

CAR-INKT

Sjoukje van der Stegen (United States)

CAR- MSC

Saad Kenderian (United States)

CAR-treg

Chiara Bonini (Italy)

Round table

All speakers

European projects and networks: T2EVOLVE Roundtable: Advanced Cellular Therapies: Collaborative Approaches to Preclinical Innovation - 17:30 - 19:00

Room Cassin

Chair: Michael Hudecek (Germany) & Maria Themeli (The Netherlands)

Opening Remark

Michael Hudecek (Germany) & Maria Themeli (The Netherlands)

Immune-Related Adverse Outcome Pathways (irAOPs) and Safety Assessment in Cellular Therapies Miriam Alb (Germany)

Preclinical Models in T2EVOLVE

Emmanuel Donnadieu (France) & Sonia Guedan (Spain)

Panel Discussion: Shaping the Future of Preclinical Models:

Data Extrapolation, Platform Technologies, and Clinical Translation in ATMPs

All speakers

Nurses Track - Session 5: Shared decision making - Why it matters - 17:30 - 19:00

Room Curie

Chairs: Michelle Kenyon (United Kingdom) & Mairead Ni Chonghaile (Ireland)

LONGITUDINAL PATIENT REPORTED OUTCOMES (PROS) OF CAR T-CELL THERAPY AND THEIR IMPACT ON SURVIVAL

Anna Spanjaart (The Netherlands)

AN EXAMINATION OF PATIENT REPORTED SIDE-EFFECTS FOR CAR-T VERSUS OTHER THERAPIES IN PATIENTS WITH RELAPSED LYMPHOMAS AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - AN ANALYSIS FROM THE LYMPHOMA COALITION'S 2024 GLOBAL PATIENT SURVEY

Natacha Bolaños (S

CARE-T: THE CAREGIVER'S PERSPECTIVE - AN EVALUATION OF SELF-PERCEIVED BURDEN AND IMPACT AMONGST CAREGIVERS OF CAR-T PATIENTS

Roberto Liu (The Netherlands)

What is shared decision making and why should we care

Jennifer Vidrine (United Kingdom)

Patient panel

All speakers

Day 3: Saturday, February 8, 2025

International session - 08:30 - 09:30

Room Schweitzer

Chairs: Nico Gagelmann (Germany) & Koray Yalcin (Türkiye)

Slovenia

Matjaz Sever (Slovenia)

Academic CAR T-cell Production in Türkiye

Siret Ratip (Türkiye)

India

Rahul Purwar (India)

Brazil

Nelson Hamershlak (Brazil)

Panel discussion

All speakers

Myeloma - 08:30 - 09:30

Room Cassin

Chairs: Sonja Zweegman (The Netherlands) & Hermann Einsele (Germany)

Special speaker

Jennifer Brudno (United States)

Academic CART-cells

Carlos Fernández de Larrea (Spain)

Commercial CART-cells

Maximilian Merz (Germany)

Bispecifics

Niels van de Donk (The Netherlands)

Optimizing Long Term Outcome of patients with B-cell lymphomas - 09:45 - 11:15

Room Schweitzer

Chair: Natacha Bolaños (Spain)

Long term outcome of CART cell therapy in patients with B-cell lymphomas (DLBCL, MCL, FL)

Andrea Kuhnl (United Kingdom)

Sequencing therapies

Gloria Iacoboni (Spain)

Treatment after relapse

Emmanuel Bachy (France)

Optimized constructs and the potential of sequential CARs in LBCL

Anne Marijn Kramer (United States)

Panel discussion

All speakers

Coffee break - 11:15 - 11:30

Keynote lecture 4 - 11:30 - 12:00

Room Schweitzer

Chairs: Anna Sureda (Spain) & Maria Themeli (The Netherlands)

Keynote Lecture

Hinrich Abken (Germany)

Best abstracts & awards & closing - 12:00 - 13:00

Room Schweitzer

Chairs: Anna Sureda (Spain) & Maria Themeli (The Netherlands)

MICROBIOME-DERIVED METABOLITES GUIDE PATIENT OUTCOME PREDICTION AND CAR-T CELL ENGINEERING

ENGINEERING Maik Luu (Germany)

PATIENT REPORTED OUTCOMES OF CAR-T CELL THERAPY: A EUROPEAN STUDY EVALUATING PATIENTS' EXPERIENCES, QUALITY OF LIFE AND UNMET CARE NEEDS - ZOOMING IN ON SOCIAL WELLBEING

Elise Pennings (The Netherlands)

FEASIBILITY OF A DECENTRALIZED ACADEMIC POINT-OF-CARE NETWORK FOR CAR-T CELL THERAPY

Mireia Bachiller (Spain)

GENERATION OF CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING P95HER2 IN SOLID TUMORS

Macarena Román Alonso (Spain)